Vanda Pharmaceuticals Inc. (VNDA)
VNDA Stock Price Chart
Explore Vanda Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze VNDA price movements and trends.
VNDA Company Profile
Discover essential business fundamentals and corporate details for Vanda Pharmaceuticals Inc. (VNDA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Apr 2006
Employees
368.00
Website
https://www.vandapharma.comCEO
Mihael H. Polymeropoulos
Description
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
VNDA Financial Timeline
Browse a chronological timeline of Vanda Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.58, while revenue estimate is $61.93m.
Earnings released on 6 May 2026
EPS came in at -$0.82 falling short of the estimated -$0.53 by -54.72%, while revenue for the quarter reached $51.72m , missing expectations by -5.93%.
Earnings released on 11 Feb 2026
EPS came in at -$0.46 surpassing the estimated -$2.18 by +78.90%, while revenue for the quarter reached $57.22m , missing expectations by -3.47%.
Earnings released on 29 Oct 2025
EPS came in at -$0.38 falling short of the estimated -$0.31 by -22.58%, while revenue for the quarter reached $56.26m , missing expectations by -5.09%.
Earnings released on 31 Jul 2025
EPS came in at -$0.46 falling short of the estimated -$0.34 by -35.29%, while revenue for the quarter reached $52.59m , missing expectations by -10.46%.
Earnings released on 7 May 2025
EPS came in at -$0.50 surpassing the estimated -$0.55 by +9.09%, while revenue for the quarter reached $50.04m , beating expectations by +10.87%.
Earnings released on 13 Feb 2025
EPS came in at -$0.08 surpassing the estimated -$0.14 by +42.86%, while revenue for the quarter reached $53.19m , beating expectations by +1.79%.
Earnings released on 6 Nov 2024
EPS came in at -$0.09 surpassing the estimated -$0.17 by +47.06%, while revenue for the quarter reached $47.65m , missing expectations by -3.05%.
Earnings released on 31 Jul 2024
EPS came in at -$0.08 surpassing the estimated -$0.21 by +61.90%, while revenue for the quarter reached $50.47m , missing expectations by -0.50%.
Earnings released on 8 May 2024
EPS came in at -$0.07 falling short of the estimated $0.05 by -240.00%, while revenue for the quarter reached $47.46m , missing expectations by -2.14%.
Earnings released on 7 Feb 2024
EPS came in at -$0.04 surpassing the estimated -$0.09 by +55.56%, while revenue for the quarter reached $45.27m , beating expectations by +22.35%.
Earnings released on 8 Nov 2023
EPS came in at $0.00 surpassing the estimated $0.00 by +100.00%, while revenue for the quarter reached $38.82m , missing expectations by -12.78%.
Earnings released on 27 Jul 2023
EPS came in at $0.03 surpassing the estimated -$0.13 by +123.08%, while revenue for the quarter reached $46.06m , missing expectations by -8.80%.
Earnings released on 3 May 2023
EPS came in at $0.06 , while revenue for the quarter reached $62.50m .
Earnings released on 8 Feb 2023
EPS came in at $0.12 surpassing the estimated $0.08 by +50.00%, while revenue for the quarter reached $64.48m , missing expectations by -4.61%.
Earnings released on 2 Nov 2022
EPS came in at $0.06 falling short of the estimated $0.09 by -33.33%, while revenue for the quarter reached $65.32m , missing expectations by -8.00%.
Earnings released on 3 Aug 2022
EPS came in at $0.05 falling short of the estimated $0.11 by -54.55%, while revenue for the quarter reached $64.39m , missing expectations by -3.90%.
Earnings released on 5 May 2022
EPS came in at -$0.11 falling short of the estimated -$0.01 by -1.00k%, while revenue for the quarter reached $60.19m , beating expectations by +3.78%.
Earnings released on 23 Feb 2022
EPS came in at $0.12 surpassing the estimated $0.09 by +33.33%, while revenue for the quarter reached $68.02m , missing expectations by -2.88%.
Earnings released on 3 Nov 2021
EPS came in at $0.14 falling short of the estimated $0.18 by -22.22%, while revenue for the quarter reached $70.10m , missing expectations by -6.54%.
Earnings released on 28 Jul 2021
EPS came in at $0.17 surpassing the estimated $0.14 by +21.43%, while revenue for the quarter reached $67.90m , missing expectations by -9.47%.
VNDA Stock Performance
Access detailed VNDA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
